Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud involving undisclosed related party transactions, channel stuffing, and inadequate internal controls during the period from August 9, 2024 to March 25, 2026. Investors who purchased ADMA securities during this period are encouraged to join the case, with a lead plaintiff deadline of August 10, 2026.